Answers are grounded in this paper and cite their sources.
Objective: This study aims to determine the relationship between polypharmacy and Coronavirus disease-2019 (COVID-19) (+) related mortality. Materials and Methods:All older adults >60 years old who had positive COVID-19 polymerase chain reaction tests were included in the study, designed retrospectively.Polypharmacy was defined as drug use of five or more.Results: One hundred and ten people of >60 years old were included in the study.Fifty-nine (53.6%) of the participants were male and the mean age was 70.5+8.81.The prevalence of polypharmacy in patients diagnosed with COVID-19 infection was 31.8% (n=35).Eighty-two (78.8%) of participants had pneumonia.Mortality occurred in 24 (21.8%) of the participants.There was no relationship between polypharmacy and mortality (p=0.241).In multivariate analysis, older age was associated with mortality (odds ratio: 6.82 95% confidence interval: 2.46-18.91,p<0.001). Conclusion:The prevalence of polypharmacy in individuals diagnosed with COVID-19 infection was like the literature.The most significant factors in death in people with COVID-19 infection were older age.There was no relationship between polypharmacy and mortality.
No takes yet. Share an insight, caveat, or question.
Durmuş et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: